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2 
Abstract 
 
Concurrent alcohol dependence poses a significant burden to health and wellbeing of people 
with established opioid dependence. Although previous research indicates that both genetic 
and environmental risk factors contribute to the development of drug or alcohol dependence, 
the role of genetic determinants in development of concurrent alcohol and opioid dependence 
has not been scrutinised. 
To search for genetic pre-determinants of concurrent alcohol and opioid dependence, 
electronic literature searches were completed using MEDLINE (PubMed) and EBSCO 
(Academic Search Complete) databases. Reference lists of included studies were also 
searched. In this discussion paper, we provide an overview of the genes (n=33) which are 
associated with the opioid, serotonergic, dopaminergic, GABA-ergic, cannabinoid, and 
metabolic systems for each dependency (i.e., alcohol or opioid) separately.  
The current evidence base is inconclusive regarding an exclusively genetic pre-determinant 
of concurrent alcohol and opioid dependence. Further search strategies and original research 
are needed to determine the genetic basis for concurrent alcohol and opioid dependency. 
 
Key words: Alcohol, Opioids, Substance-related disorders, Comorbidity, Genetic 
predisposition 
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Introduction 
Problem opioid use is highly prevalent in Europe, including high rates in Ireland of seven per  
1000 (1). Opioids are responsible for the highest rate of drug-related morbidity and mortality, 
contributing to greater than 77% of drug induced fatalities in Europe (1). Concurrent alcohol 
dependence poses a significant burden to the health care of people with established opioid 
dependence (2). Its negative impacts on addiction treatment include behaviours leading to 
clinical management difficulties, e.g., illicit drug use or non-adherence with clinicians’ 
advice and early drop out (3)  
 
Multiple studies have confirmed that both gene-gene and gene-environment interactions 
contribute to the development of drug dependence or alcohol dependence alone (4). Alcohol 
dependence has been associated with polymorphisms in genes coding for opioid receptors, 
serotonin receptors, GABA-ergic receptors, nicotinic and muscarinic acetylcholine receptors, 
CREB genes involved in familial predisposition to alcohol (cyclic AMP responsive element 
binding protein), and alcohol dehydrogenase (5). Opioid dependence has been associated 
with opioid system genes, particularly the mu-opioid receptor gene PKNOX2, as well as the 
dopaminergic system (6). Genome-wide association studies of multiple addictions have 
discussed potential vulnerability genes, more specifically cell adhesion genes that control the 
formation, stabilization, enhancement, and elimination of contacts between brain cells (7). 
A previous review has discussed several genes associated with multiple addictions; however, 
the contribution of genes to concurrent alcohol and opioid dependence has been neglected to 
date (4). 
 
Clinical experience suggests that alcohol and opioid dependence may have common genetic 
aetiological origin. For example, Naltrexone (an opiate antagonist) is useful in the treatment 
of alcohol dependence (8). Most psychotropic substances (apart from benzodiazepines) have 
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been shown to directly or indirectly increase dopaminergic activity in the "reward pathway" 
(Nucleus Accumbans  - Ventral Tegmental Area - pre frontal cortex) (1). Alcohol and opiates 
both stimulate the mu-opioid receptor on the GABA neuron thereby inhibiting its activity in 
GABA. This, in turn, reduces the inhibitory effect of GABA on the dopaminergic system in 
nucleus accumbans and the pre frontal cortex. Studies have found elevations of mu-opioid 
receptors in people with alcohol dependence (9). Higher observed rates of alcohol 
dependence in parents of adults with heroin dependence raise the possibility of a common 
risk factor. Another clinical reality is that early onset drinking may be associated with 
subsequent heroin dependence. Alcohol dependence in this cohort tends to become evident 
only after entry into opioid substitution treatment, following cessation or dramatic reduction 
in heroin use (10). . Taken together, clinical evidence suggests the possibility of a common 
genetic link between opioid and alcohol dependence but the nature of that link remains 
unclear. 
The aim of the present study was to critically review genetic pre-determinants of concurrent 
alcohol and opioid dependence through an electronic search of the relevant literature. 
Electronic searches were completed using MEDLINE (PubMed) and EBSCO (Academic 
Search Complete) databases.  
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Discussion 
 
Twenty included studies examined the role of 33 genes in alcohol or opioid dependence. 
They were associated with the opioid, cholinergic, serotonergic, dopaminergic, GABA-ergic, 
cannabinoid, and metabolic systems. The identified genes classified by their system and 
function are presented in Table 1. <instruction for editors: insert Table 1 here> 
 
Opioid system 
Seven studies investigated the role of genes in the opioid system (11-18). Genes encoding all 
three types of opioid receptors were studied with variable results. Kumar et al., (2012) and 
Deb et al., (2010) concluded that the A118G polymorphism of OPRM1 (mu-opioid receptor 
gene) was associated with alcohol and opioid addiction in males in Eastern India (16, 17). 
Kumar et al., (2012) found that people with alcohol dependence and heroin dependence were 
1.7 times and 1.9 times more likely, respectively, than control subjects to have the A11G 
polymorphism (16). Deb et al., (2010) found that subjects with alcohol dependence and 
opioid dependence were more likely than control to have the A11G polymorphism (17). 
However, a study conducted in Germany by Franke et al., (2001) found no difference in the 
frequency of the A118G polymorphism between heroin or alcohol dependent subjects and 
controls (15). In addition to the A118G single nucleotide polymorphism (SNP), Luo et al., 
(2003) found that the allele -2442A of OPRM1 was associated with concurrent alcohol and 
opioid dependence in European Americans, but not in African Americans (13). 
Zhang et al., (2008) conducted the only apparent study to associate the delta opioid receptor 
gene (OPRD1) with alcohol and opioid addiction. They found that the GCAACT haplotype 
containing G80T G-allele and C921T C-allele was associated with an increased risk of 
alcohol dependence (OR= 6.43) and opioid addiction (OR= 50.57) (11). Franke et al., (1999) 
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studied  the silent T to C substitution at position 921 and found no association between this 
polymorphism and alcohol or opioid addiction (14). Similarly, Xuei et al., (2007) used a 
family-based association to investigate the opioid system in alcohol and drug dependence by 
analyzing the genes encoding the micro- and delta-opioid receptors and their peptide ligands. 
They found no significant associations of the OPRM1, OPRD1, PENK and POMC genes 
with alcohol or illicit drug dependence (18). In summary, the results of opioid receptors are 
variable with OPRMI being most promising. 
 
Dopaminergic system 
A study by Yang et al., (2008) analysed the cluster of genes functionally associated with the 
dopaminergic system on chromosome 11q23. These genes included DRD2, TTC12, ANKK1, 
and NCAM1. They concluded that variants in TTC12 exon 3, NCAM1 exon 12, and the two 
3'-ends of ANKK1 and DRD2 co-regulate risk for concurrent alcohol dependence and drug 
dependence (19). This co-regulation may play a role in concurrent dependencies, but we 
found only one study with such result. 
 
Alcohol dehydrogenase (ADH) 
A total of seven ADH genes (ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, and ADH7) 
were analysed in two separate studies (20, 21). It is important to note that this was a recessive 
association. Two ADH4 single nucleotide polymorphisms (SNPs) (rs1042363 and rs1800759) 
showed Hardy-Weinberg disequilibrium in Americans of European origin but not in controls 
(20). Two SNPs were more likely to be associated with concurrent drug and alcohol 
dependence in European Americans (ADH5 rs1154400, ADH7 rs1573496), compared to drug 
dependence alone (21). One SNP was associated with concurrent drug and alcohol 
dependence in African Americans (ADH1C rs1693482) and one SNP was associated with 
concurrent drug and alcohol dependence in both populations (ADH1B rs1229984) (21). It 
seems that the ADH genes function in concurrent dependencies is population-specific. 
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Cholinergic 
Genes for both muscarinic and nicotinic cholinergic receptors play a significant role in 
concurrent alcohol and opioid dependence (22, 23). Dick et al., (2007) found 11 SNPs of 
muscarinic acetylcholine receptor gene (CHRM2) to be significant for individuals with 
alcohol dependence and concurrent drug dependence. These SNPs were not found to be 
associated with alcohol dependence alone (22). Sherva et al., (2010) investigated the role of 
the nicotinic gene cluster on chromosome 15q25.1 in case-control and family-based 
association studies. They found that multiple SNPs were associated with substance 
dependence, but only one SNP (rs16969968) was associated with both alcohol dependence 
and opioid dependence (23). 
 
Serotonergic 
Two studies have examined the role of the serotonergic system (24, 25) focusing on the 5HT-
transporter gene, SLC 6A4. Saiz et al., (2009) found no significant differences in the 
genotypic frequencies of the 5-HTTLPR and STin2 VNTR polymorphisms of SLC 6A4 
between subjects with heroin addiction, alcohol addiction, or controls. This study also did not 
find an association between HTR2A A-1438G polymorphism and alcohol or opioid addiction 
(25). Enoch et al., (2011) found that low 5-HTTLPR activity and the HTR2B Ser 129 allele 
were more common in men with concurrent alcohol and drug dependence compared to 
controls. Together, they had an additive effect. The study also found no association between 
HTR3A haplotype and alcohol or drug dependence (24). Serotogenic system appears to be 
less important for concurrent dependencies. 
 
GABA-ergic 
Three studies investigated the role of GABA-receptor genes in substance dependence (26-
28). A fuzzy clustering analysis performed by Yang et al., (2012) on 1758 individuals in 
8 
families with two siblings with alcohol, opioid, or cocaine dependence showed a significant 
linkage signal in chromosome 4 in European Americans. The location of the linkage peak 
corresponds with GABRA4, GABRB1, and CLOCK. A second suggestive linkage peak was 
also found on chromosome 21. In African Americans, suggestive linkage peaks were found 
on chromosomes 10, 3, and 9. No linkage peaks were found on chromosome 4 in African 
Americans (26). 
A family based association study conducted by Agrawal et al., (2006) found an association 
between five GABRA2 SNPs and concurrent alcohol and drug dependence.. No association 
was found with any other GABAA receptor genes (GABRA2, GABRA4, GABRB1, GBRG2) 
(27). On the whole, some GABA-ergic genes can be relevant for concurrent dependencies, 
but no GABAA receptor genes. 
 
IL-B 
A case control study from Australia found that IL-1B -511C and -31T alleles were more 
frequent in both opioid- and alcohol-dependent patients compared with controls (29). While 
the higher frequency of these alleles in both dependencies may suggest a link with concurrent 
dependencies, only one study showed such results. 
 
Nociception 
Xuei et al., (2008) conducted a study on the role of the nociception receptor gene (OPRL1) 
and its ligand (PNOC) on substance dependence in European Americans. SNPs in PNOC 
showed marginal association with alcohol dependence rs17058952 (p=0.05). Two adjacent 
SNPs in intron 1 of OPRL1 were marginally associated with opioid dependence (rs6512305 
(p=0.05), and rs6090043 (p=0.05)). However, neither gene showed association with both 
alcohol and opioid dependence (12). 
 
9 
Cannabinoid 
A study conducted by Zuo et al., (2007) found that for European Americans, the risk for 
developing substance dependence significantly increased with the number of “G” alleles at 
rs6454674 in the cannabinoid receptor gene (CNR1). Interaction between rs6454674 and 
rs806368 had a significant risk factor for alcohol dependence, drug dependence cocaine 
and/or alcohol dependence, and concurrent alcohol and drug dependence (30). 
 
Future research 
Some evidence suggests that muscarinic acetylcholine receptor gene (CHRM2) may be 
implicated in concurrent alcohol and opioid dependence; similarly, dopaminergic 
mechanisms are very likely to be relevant to both dependencies. Like most conditions, none 
of those genes can be identified as their sole genetic pre-determinant. The impact of genes on 
concurrent dependence results at least in part from the combined effects of multiple genes 
(4).  
Many other addictions also commonly coexist with opioid dependence, e.g. cannabis, 
benzodiazepines, or tobacco (4). Current neurobiological theories of addiction suggest that 
people with hypo-activity of dopamine system may be more vulnerable to developing all 
addictions (4). Also, current theory on mechanism of addiction centres on impairment of 
ability of pre-frontal cortex to inhibit hedonic activity, i.e. past drug use damages the brain’s 
‘braking’ system, making it harder to resist impulse to use again in future (9).  Therefore, if 
one has a genetically caused dopaminergic hypo-activity or a prefrontal cortex more prone 
(genetically) to damage by past addiction to other substance, one may be more likely to 
develop any other addiction. Hence, if there are genes that are associated with increased risk 
of alcohol dependence in people who are dependent on opioids, some of these genes may 
cause a specific increase in risk of alcohol dependence, while others may just cause a general 
increase in all other addictions, including alcohol. 
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Multiple studies confirmed that both gene-gene and gene-environment interactions contribute 
to the development of drug dependence or alcohol dependence (4). This is consistent with the 
notion that no condition should be studied in isolation. Gene expression is as important as 
gene-environment interaction and individual upbringing or personality, all of which influence 
dependence. Therefore, a systematic review on the relationships between genes and 
environment (including social and/or psychological sequel) is needed to provide context 
necessary for identification of genetic predeterminants of a concurrent dependence. 
Many studies were conducted by the same group of researchers; they studied cohorts of 
European-Americans and African-American sub-populations (11, 13, 19, 23, 30). None of 
those studies were performed in Ireland or the United Kingdom. This omission provides an 
opportunity for further exploration in these countries. Ireland is located on the Western edge 
of Europe and may have a different gene pool compared to the rest of Europe. Additionally, 
Ireland has the third highest per capita alcohol consumption in Europe as well as the highest 
rate of binge drinking (1). Moreover, such observation underscores the need to carefully 
identify the ethnic origins of each sub-population, as the prevalence of a given polymorphism 
can vary across populations. For example, the prevalence of the A118G variant of the mu 
opioid receptor gene varies from 2-49% among different ethnic groups (31). Asian ‘glow’ is 
yet another, well recognised example of how ethnicity can impact upon genetic expression 
that is relevant to alcohol use. These polymorphisms may account for the varying results 
among European, African American or Asian studies.  
It is also likely that the genes responsible for addictive disorders are present in a much greater 
percentage of the population than the phenotype due to a limited availability of illicit 
substances such as opioids.  For future case control studies we suggest that the control groups 
should consist of people with opioid dependencies who were non-dependent alcohol drinkers. 
From a clinical perspective, the issue of dual dependence tends to be a concern in one 
direction only. Treatment providers don't encounter substantial numbers of people with 
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alcohol dependence going on to become opioid dependent. Only a minority of patients treated 
for alcohol dependence ever use illicit opioids. One could speculate that while they may have 
high risk gene for development of opioid dependence this risk never becomes manifest in the 
absence of use of that class of drugs. However, almost everyone who is opioid dependent will 
have had exposure to alcohol use. Hence, if they had a risky gene, it would be quite likely to 
manifest itself. 
Finally, we suggest that examining the genetic pre-determinants feature prominently in future 
research endeavours among problem drug users, especially in geographical regions with a 
high prevalence of concurrent alcohol and opioid dependency.   
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Conclusion 
On the basis of the electronic search of relevant literature, the current evidence base is 
inconclusive regarding an exclusively genetic pre-determinant of concurrent alcohol and 
opioid dependence. A systematic review of literature is needed; however, our findings do 
have some immediate implications for study design. Trials should use precise and consistent 
criteria for selection of subjects with dual drug dependence. Future case control studies 
should have control groups that consist of people with opioid dependencies who are non-
dependent problem alcohol users. Future investigations of the genetic pre-determinants of 
these concurrent problems should focus on high-risk populations and regions.  
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Table 1 Summary of genes, included studies and their characteristics 
Genes identified as having a potential role in concurrent alcohol and opioid dependence. 
Genes Function System Study characteristics 
   Type(s) of study Sample Size Setting/ Participants Author 
GABRA2 
GABRA4 
GABRB1 
GBRG2  
Receptor 
Receptor  
Receptor 
Receptor 
GABA-ergic 
GABA-ergic 
GABA-ergic 
GABA-ergic 
Family based 
association 
2286 European and African Americans Agrawal, et al., 2006 
OPRM1 Receptor Opioid Case-control 222 Bengali-Hindu Indians Deb, et al., 2010 
CHRM2  Receptor Cholinergic Family based 
association 
2282 European and African Americans Dick, et al., 2007 
HTR3A 
HTR3B 
SLC 6A4  
Receptor 
Receptor 
Transporter 
Serotogenic 
Serotogenic 
Serotogenic 
Case-control 547 African American males Enoch, et al., 2011 
GABRA2 Receptor GABA-ergic Retrospective case-
control 
832 African American males Enoch, et al., 2011 
OPRM1 Receptor Opioid Case-control, family 
control 
873 (186) Germans Franke, et al., 2001 
OPRD1 Receptor Opioid Case-control, family 
based association 
668 (162) Germans Franke, et al., 1999 
OPRK1 
OPRM1 
Receptor 
Receptor 
Opioid 
Opioid 
Case-control 440 Bengali-Hindu Indians Kumar, et al., 2012 
IL-1B Cytokine Inflamatory Case-control 219 European Australians Liu, et al., 2009 
OPRM1 Receptor Opioid Case-control 676 European and African Americans Luo, et al., 2003 
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ADH4 Metabolism Alcohol 
metabolism 
Case-control 926 European and African Americans Luo, et al., 2006 
ADH1A 
ADH1B 
ADH1C 
ADH4  
ADH5  
ADH6  
ADH7 
Metabolism 
Metabolism 
Metabolism 
Metabolism 
Metabolism 
Metabolism 
Metabolism 
Alcohol 
metabolism 
Alcohol 
metabolism 
Alcohol 
metabolism 
Alcohol 
metabolism 
Alcohol 
metabolism 
Alcohol 
metabolism 
Alcohol 
metabolism 
Case-control 718 European and African Americans Luo, et al., 2007 
HTR2A  
SLC6A4 
Receptor 
Transporter 
Serotonergic 
Serotonergic 
Case-control 698 Spanish Saiz, et al., 2009 
CHRNA5  
CHRNA3  
CHRNB4  
Receptor 
Receptor 
Receptor 
Cholinergic 
Cholinergic 
Cholinergic 
Case-control, family 
based association 
3388, 1858 European and African Americans Sherva, et al., 2010 
OPRL1  
PNOC 
Receptor 
Ligand 
Nociception 
Nociception 
Family based 
association 
1923 European Americans Xuei, et al., 2008 
OPRM1  
OPRD1  
PENK  
POMC 
Receptor 
Receptor 
Ligand 
Ligand 
Opioid 
Opioid 
Opioid 
Opioid 
Family based 
association 
1923 European Americans Xuei, et al., 2007 
GABRA4  
GABRB1  
CLOCK 
Receptor 
Receptor 
Transcription factor 
GABA-ergic 
Gaba-ergic 
Generation of 
circadian rhythm 
Fuzzy clustering 
analysis 
1758 European and African Americans Yang, et al., 2012 
20 
NCAM1  
TTC12  
ANKK1  
DRD2  
Cell adhesion 
Tumour suppressor 
Signal transduction 
Receptor 
Dopaminergic 
Dopaminergic 
Dopaminergic 
Dopaminergic 
Case-control, family 
based association 
302, 1090 European Americans Yang, et al., 2008 
OPRD1  
OPRK1  
Receptor 
Receptor 
Opioid 
Opioid 
Case-control 1063 European Americans Zhang, et al., 2008 
CNR1 Receptor Canabinoidergic Case-control 1001 European and African Americans Zuo, et al., 2007 
 
